<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Wilson disease: Management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Wilson disease: Management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Wilson disease: Management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael L Schilsky, MD, FAASLD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bruce A Runyon, MD, FAASLD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Wilson disease (also referred to as hepatolenticular degeneration) is a genetic disorder of copper metabolism with an autosomal recessive pattern of inheritance that leads to impaired function of the intracellular copper transporter ATP7B. Reduced biliary excretion of copper leads to its accumulation in the liver and other tissues (eg, brain, cornea). Most patients present with liver disease that ranges from asymptomatic elevations in serum aminotransferases or bilirubin to acute liver failure or chronic hepatitis. In addition, some patients develop neuropsychiatric symptoms. (See  <a class="medical medical_review" href="/z/d/html/83837.html" rel="external">"Wilson disease: Clinical manifestations, diagnosis, and natural history", section on 'Clinical features'</a>.)</p><p>This topic will discuss management of Wilson disease. Other aspects of Wilson disease, including screening asymptomatic relatives, are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Epidemiology and pathogenesis – (See  <a class="medical medical_review" href="/z/d/html/3626.html" rel="external">"Wilson disease: Epidemiology and pathogenesis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical manifestations and diagnosis – (See  <a class="medical medical_review" href="/z/d/html/83837.html" rel="external">"Wilson disease: Clinical manifestations, diagnosis, and natural history"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Interpretation of genetic testing for <em>ATP7B</em> (Wilson disease gene) – (See  <a class="medical medical_review" href="/z/d/html/131793.html" rel="external">"Gene test interpretation: <i>ATP7B</i> (Wilson disease gene)"</a>.)</p><p></p><p class="headingAnchor" id="H30146491"><span class="h1">PRETREATMENT EVALUATION</span><span class="headingEndMark"> — </span>Prior to initiating pharmacologic therapy, we obtain or review the following studies:</p><p class="bulletIndent2"><span class="glyph">•</span>24-hour urinary copper excretion</p><p class="bulletIndent2"><span class="glyph">•</span>Ceruloplasmin</p><p class="bulletIndent2"><span class="glyph">•</span>International normalized ratio (INR)</p><p class="bulletIndent2"><span class="glyph">•</span>Iron studies and ferritin</p><p class="bulletIndent2"><span class="glyph">•</span>Serum aminotransferases – Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)</p><p class="bulletIndent2"><span class="glyph">•</span>Serum copper</p><p class="bulletIndent2"><span class="glyph">•</span>Serum creatinine</p><p class="bulletIndent2"><span class="glyph">•</span>Serum sodium</p><p class="bulletIndent2"><span class="glyph">•</span>Total bilirubin</p><p class="bulletIndent2"><span class="glyph">•</span>Uric acid [<a href="#rid1">1</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Urinalysis</p><p></p><p>We use values for total bilirubin, INR, serum creatinine, and serum sodium to calculate the Model for End-stage Liver Disease (MELD) score. (See  <a class="medical medical_review" href="/z/d/html/1241.html" rel="external">"Model for End-stage Liver Disease (MELD)"</a>.)</p><p>If a liver biopsy was not performed during the diagnostic evaluation, we obtain ultrasound-based transient elastography to evaluate for liver fibrosis. (See  <a class="medical medical_review" href="/z/d/html/96717.html" rel="external">"Noninvasive assessment of hepatic fibrosis: Ultrasound-based elastography"</a> and <a class="local">'Patients with cirrhosis'</a> below.)</p><p>Baseline studies are used for assessing disease activity and monitoring response to therapy.</p><p class="headingAnchor" id="H1992515514"><span class="h1">TREATMENT GOALS</span><span class="headingEndMark"> — </span>Goals of therapy for Wilson disease include:</p><p class="bulletIndent1"><span class="glyph">●</span>Removing copper that has accumulated in tissue</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preventing copper from reaccumulating in tissue</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Improving symptoms (or preventing the development of symptoms)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Improving and maintaining liver synthetic function (eg, resolution of jaundice, ascites, correcting abnormalities in coagulation and in serum albumin)</p><p></p><p class="headingAnchor" id="H3281134584"><span class="h1">INITIAL MANAGEMENT</span></p><p class="headingAnchor" id="H2600746146"><span class="h2">General measures</span><span class="headingEndMark"> — </span>The following measures apply to patients with Wilson disease:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dietary modifications</strong> – During the initial phase of treatment, patients should avoid consuming food with high copper content (ie, shellfish, nuts, chocolate, mushrooms, and organ meats). However, dietary copper restriction is insufficient as sole therapy for Wilson disease. </p><p></p><p class="bulletIndent1">For patients who are stable on maintenance therapy, moderate intake of copper (eg, &lt;2 mg copper daily) may be reasonable.<strong> </strong>A detailed list of the mineral content of foods is available on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffdc.nal.usda.gov%2F&amp;token=YRvsg6S0dX25uLS7m4P5uJEU7qlTdokoB336745NsmgxbU0Ad45yx1WsPc86EH7R&amp;TOPIC_ID=3591" target="_blank">United States Department of Agriculture website</a>.<strong>  </strong></p><p></p><p class="bulletIndent1">We advise patients who consume well water to test the water for copper content or use filters that remove trace elements. Municipal water supplies usually do not require analysis. We also advise patients who have copper pipes in the household to flush the system (ie, run the water until it is cool) before each use when using water for cooking or consumption. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunizations</strong> – Vaccinations for hepatitis A virus and hepatitis B virus are given to patients without serologic evidence of immunity. Additional vaccines for patients with chronic liver disease include immunizations that are given to the general population (eg, influenza). Immunization schedules are described separately. (See  <a class="medical medical_review" href="/z/d/html/3891.html" rel="external">"Immunizations for adults with chronic liver disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abstain from alcohol </strong>–<strong> </strong>We advise patients to abstain from alcohol and, in particular, to avoid heavy alcohol use (ie, &gt;14 drinks per week or &gt;4 drinks on a given day for males and &gt;7 drinks per week or &gt;3 drinks on a given day for females) [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specialty referrals</strong> – We suggest that patients with Wilson disease are referred to a hepatologist for long-term management. In addition, we refer patients with neurologic symptoms (eg, tremor) to a neurologist with expertise in movement disorders. Other referrals include psychiatry for patients with psychiatric symptoms, registered dieticians for nutritional counseling, and genetic counseling for molecular genetic testing if genetic testing was not performed as part of the diagnostic evaluation. (See  <a class="medical medical_review" href="/z/d/html/83837.html" rel="external">"Wilson disease: Clinical manifestations, diagnosis, and natural history", section on 'Diagnostic evaluation'</a>.)</p><p></p><p class="headingAnchor" id="H4203883164"><span class="h2">Selecting initial therapy</span><span class="headingEndMark"> — </span>Selecting an initial therapy is informed by whether the patient has symptoms and/or evidence of organ damage related to copper accumulation (eg, asymptomatic hepatomegaly or persistently elevated aminotransferases). Asymptomatic patients with Wilson disease are typically diagnosed when they undergo screening because they are a blood relative of a patient with Wilson disease. (See <a class="local">'Patients with symptoms and/or organ damage'</a> below and <a class="local">'Asymptomatic patients without organ damage'</a> below.) </p><p class="headingAnchor" id="H1239212488"><span class="h3">Patients with symptoms and/or organ damage</span><span class="headingEndMark"> — </span>Copper chelating agents (ie, <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a>, <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a>) are first-line therapy for patients with Wilson disease who have symptoms and/or organ damage  (<a class="graphic graphic_algorithm graphicRef142796" href="/z/d/graphic/142796.html" rel="external">algorithm 1</a>). Selecting an agent is individualized and informed by published data, drug safety profile, patient comorbidities, clinical experience, drug availability, and cost. D-penicillamine has been commonly used for initial treatment [<a href="#rid3">3</a>]. However, trientine is also a reasonable option for initial therapy. In addition, we typically use trientine for patients who develop or are at risk for toxicity from D-penicillamine. Patients at risk for D-penicillamine-associated toxicity include those with kidney disease or severe thrombocytopenia (eg, platelet count &lt;40,000/microL). (See <a class="local">'Drug dosing and administration'</a> below.) </p><p>Most patients have some improvement in symptoms and liver biochemistries in two to six months after initiating therapy. Many patients continue to improve beyond six months, with stabilization of liver synthetic function occurring somewhere between 6 and 18 months. For clinical symptoms, improvement can continue gradually for several years. </p><p>The use of chelating agents is supported by data from observational studies and clinical experience [<a href="#rid4">4-16</a>]. In a retrospective study of 231 patients with symptomatic Wilson disease, rates of improvement in liver-related symptoms and/or biochemistries were not significantly different for patients treated with <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> compared with <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a> after 48 months (91 versus 93 percent) [<a href="#rid11">11</a>]. Rates of progressive liver disease were also not significantly different between the groups (2 versus 0 percent). In addition, rates of neurologic improvement were not significantly different between the groups. However, D-penicillamine was associated with lower rates of progressive neurologic symptoms (2 versus 10 percent).</p><p>Limited data suggested that chelating therapy was more effective for preventing progressive liver disease than oral zinc [<a href="#rid17">17,18</a>]. In a retrospective study including 288 patients with Wilson disease who were followed for a median of 17 years, zinc monotherapy was associated with higher rates of treatment failure (defined as increased liver biochemistries) compared with a chelating agent (16 versus 1 percent) [<a href="#rid18">18</a>]. In addition, patients who did not respond to zinc monotherapy had improvement in liver biochemistries after switching to chelating therapy.</p><p>Data from small retrospective studies suggested that <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a> was effective for treating patients with adverse effects from <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a>. In two studies including 41 patients with Wilson disease who did not tolerate D-penicillamine, the trientine formulation, triethylene tetramine dihydrochloride, was associated with symptomatic improvement in 34 patients (83 percent) after a mean of 49 months of follow-up [<a href="#rid19">19</a>]. Four patients (10 percent) had no change in symptoms, and one patient had progressive symptoms. Two patients were lost to follow-up. </p><p class="headingAnchor" id="H3222462088"><span class="h3">Asymptomatic patients without organ damage</span><span class="headingEndMark"> — </span>We treat asymptomatic patients without organ damage with either a chelating agent (ie, <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> or <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a>) or zinc [<a href="#rid20">20,21</a>]. </p><p>For patients who begin a chelating agent, we typically use maintenance dosing (ie, a lower dose than induction dosing). (See <a class="local">'Drug dosing and administration'</a> below.)</p><p>Most asymptomatic patients do not develop symptoms while on therapy. </p><p>Most studies supporting the use of zinc for asymptomatic patients involve pediatric populations who were diagnosed following screening for Wilson disease because of a positive family history [<a href="#rid22">22-26</a>]. In an observational study including 22 pediatric patients with asymptomatic Wilson disease who were treated with oral zinc therapy for 10 years, 21 patients (95 percent) had normalization of alanine aminotransferase (ALT) levels after 10 years, and no patients developed symptomatic liver disease [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H2"><span class="h2">Drug dosing and administration</span></p><p class="headingAnchor" id="H4"><span class="h3">D-penicillamine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> contains a free sulfhydryl group that functions as a copper chelating moiety. Its major effect is to remove copper from less tightly bound sites on proteins, peptides, and membranes, and promote its renal excretion. In addition, D-penicillamine may also function by other mechanisms such as stimulation of endogenous metallothionein. </p><p><a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> is absorbed rapidly from the gastrointestinal tract [<a href="#rid27">27</a>]. Its absorption is decreased by as much as 50 percent when taken with food. More than 80 percent is excreted by the kidneys. Its half-life is in the range of 1.7 to 7 hours [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H6"><span class="h4">Dosing</span><span class="headingEndMark"> — </span>For adults who weigh ≥45 kg, we begin <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> with a dose of 250 to 500 mg orally once daily. We then increase the dose in 250 mg increments every four to seven days to a maximum dose of 1500 mg per day, given in two to four divided doses. For adults who weigh &lt;45 kg and for pediatric patients, we begin with 250 mg orally once daily. We then increase the dose in 250 mg increments every four to seven days to a maximum total daily dose of 20 mg/kg (rounded to the nearest 250 mg) or approximately 1000 mg per day in two or three divided doses. Gradually increasing the dose may lower the risk of immediate adverse effects such as fever and rash, but it does not appear to lower the risk of late-onset toxicity, such as nephrotic syndrome. (See <a class="local">'Adverse effects'</a> below.)</p><p>If <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> is used long term, we usually add <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">pyridoxine</a> (vitamin B6) supplementation (25 to 50 mg/day) since D-penicillamine may cause pyridoxine deficiency. (See  <a class="medical medical_review" href="/z/d/html/5367.html" rel="external">"Overview of water-soluble vitamins", section on 'Vitamin B6 (pyridoxine)'</a>.)</p><p>For maintenance dosing, we lower the total dose to 750 to 1000 mg daily, given in two divided doses. When a biochemical response to adjusting the maintenance dose occurs, it may not be seen for up to six weeks after adjusting the dose. (See <a class="local">'Patients who respond to drug therapy'</a> below.)</p><p>We typically instruct patients to take <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> one hour before or two hours after meals because food interferes with its absorption.</p><p class="headingAnchor" id="H8"><span class="h4">Adverse effects</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> is associated with multiple adverse effects that result in discontinuing therapy in approximately 30 percent of patients [<a href="#rid29">29</a>]. In addition, cross-reactivity to penicillin may occur. Thus, for patients with penicillin allergy, we use the drug cautiously or use an alternative agent (eg, <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a>). </p><p>Adverse effects may be classified by timing of the event:</p><p class="bulletIndent1"><span class="glyph">●</span>Early adverse effects – Early sensitivity reactions occur within one to three weeks of initiating therapy and include fever, rash, lymphadenopathy, neutropenia, thrombocytopenia, and proteinuria. For patients who develop early side effects, we discontinue <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> immediately and initiate an alternative agent such as <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a>. (See <a class="local">'Trientine'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Late adverse effects – Later reactions develop after months to years of therapy and include the following (see <a class="local">'Drug monitoring'</a> below):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Exacerbated neurologic disease – For patients with predominantly neurologic disease, initiating <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> may worsen neurologic symptoms in approximately 20 percent of such patients [<a href="#rid30">30-32</a>]. In addition, some patients develop new neurologic symptoms. In a series of 143 patients with Wilson disease, 16 patients (23 percent) with neurologic disease had worsening neurologic status with a median time of onset of 2.3 months after initiating treatment [<a href="#rid30">30</a>]. Exacerbation of neurologic symptoms may be related to mobilization of liver copper stores that increases brain copper exposure or to the development of intracellular copper complexes.</p><p></p><p class="bulletIndent2">For patients who develop worsening neurologic symptoms (other than loss of taste), we typically discontinue <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> and begin an alternative agent (eg, <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a> or zinc). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Kidney toxicity – Kidney toxicity is typically manifested by proteinuria, or less commonly, crescentic glomerulonephritis [<a href="#rid33">33</a>]. We discontinue <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> if the patient develops nephrotic syndrome. Proteinuria typically resolves several months after stopping the drug [<a href="#rid34">34</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bone marrow toxicity – Bone marrow toxicity with thrombocytopenia or aplastic anemia is rare but may not be reversible.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dermatologic effects – Skin changes include elastosis perforans serpiginosa, lichen planus, aphthous stomatitis, bullous pemphigoid, and pseudoxanthoma elasticum [<a href="#rid35">35-38</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other side effects – Other late reactions include anti-GBM (Goodpasture) disease, myasthenia gravis, polymyositis, hepatotoxicity, hepatic siderosis/iron overload, loss of taste, and a lupus-like syndrome characterized by hematuria, proteinuria, and a positive antinuclear antibody [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1">Gastrointestinal side effects may occur at any time during therapy and include nausea, vomiting, and anorexia. These symptoms are dose-related signs of gastric irritation, and they improve with reducing the dose.</p><p></p><p class="headingAnchor" id="H9"><span class="h4">Drug monitoring</span><span class="headingEndMark"> — </span>We obtain a complete blood count, urinalysis, and serum creatinine after the first week and then once a month during the first three months; at three-month intervals until target urinary copper levels are achieved; and twice per year thereafter.  </p><p>We discontinue <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> for patients who develop leukopenia (white blood cell count &lt;3000/microL), neutropenia (neutrophil count &lt;2000/microL), thrombocytopenia (platelet count &lt;80,000/microL if pretreatment baseline value was ≥150,000/microL), or if a steady decline over three successive tests is observed, even though the counts remain above the threshold value for discontinuation. Monitoring patients with cirrhosis who are treated with D-penicillamine is discussed below. (See <a class="local">'Patients with cirrhosis'</a> below.)</p><p>We obtain iron studies and ferritin if there is a decrease in hemoglobin or concern for overtreatment (typically after many years of therapy). </p><p>We measure 24-hour urine for protein if urinalysis shows new or worsening proteinuria. We typically discontinue <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> if proteinuria exceeds 2+ on a dipstick and is confirmed with 24-hour urine for protein, if red cell or white casts are observed at microscopic examination of the urine, or if more than 10 red cells are seen per high-power field. For such patients, we switch to <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a> or zinc. However, some hepatologists continue D-penicillamine if quantitative proteinuria does not exceed 1 g/day and is not trending upward. For patients with proteinuria exceeding 2 g/day or a down-trending glomerular filtration rate, we permanently discontinue D-penicillamine. (See  <a class="medical medical_review" href="/z/d/html/3101.html" rel="external">"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults", section on 'Detection and measurement of total urinary protein excretion'</a>.) </p><p>We assess adherence to the drug regimen by measuring 24-hour urinary copper excretion. However, a rise in urinary copper after previously achieving the target level may be related to higher dietary copper intake or lack of adherence to the drug regimen. History from the patient or caregivers can help determine which of these etiologies is likely. In addition, when the dose of <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> is increased, the urinary copper excretion may also increase and does not reflect nonadherence. This occurs because binding of copper to D-penicillamine is stoichiometric, thus, the amount of copper excreted in the urine will increase with increasing dosing of D-penicillamine. </p><p class="headingAnchor" id="H12"><span class="h3">Trientine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">Trientine</a> is a copper chelator that is available in several formulations including triethylene tetramine dihydrochloride (also referred to as trientine hydrochloride) and trientine tetrahydrochloride [<a href="#rid40">40</a>]. Trientine differs from <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> by lacking sulfhydryl groups, and it chelates copper by forming a stable complex with its four constituent nitrogens. Trientine functions principally by removing copper from less strongly bound sites on proteins and membranes and by increasing renal copper excretion. In addition, the non-absorbed drug may block intestinal absorption of copper. (See <a class="local">'Dosing'</a> below.) </p><p>On a mole for mole basis, more copper is excreted in the urine following use of <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> than <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a>. However, the potential action of non-absorbed trientine to block dietary copper uptake allows for achieving goals of therapy with comparable dosages. (See <a class="local">'Treatment goals'</a> above.)</p><p>The pharmacokinetics of <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a> have not been well studied. It is poorly absorbed; only 1 percent of the ingested amount (and 8 percent of its principal metabolite, acetyltrien) is excreted in the urine. The amount of iron, zinc, and copper chelated correlates with the amount of trientine in the urine [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H14"><span class="h4">Dosing</span><span class="headingEndMark"> — </span>For adults, the initial dose of triethylene tetramine dihydrochloride is 15 to 20 mg/kg per day (up to a maximum dose of 1500 mg) in two or three divided doses. Maintenance dosing is approximately 15 mg/kg per day (up to a maximum dose of 1500 mg) given in two or three divided doses.</p><p>For pediatric patients, the initial dose is 20 mg/kg per day, rounded to the nearest 250 mg, given in two or three divided doses. Maintenance dosing is 10 to 15 mg/kg per day, given in two or three divided doses.</p><p>We instruct patients to take <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a> ideally one hour before or two hours after meals. The drug is not stable at high temperatures and requires refrigerated storage. </p><p>We do not use once daily <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a> dosing, but it has been studied for increasing adherence and ease of maintenance dosing [<a href="#rid42">42</a>]. Further studies are needed to confirm efficacy and safety of this dosing regimen.</p><p>Another formulation, <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a> tetrahydrochloride, has been approved by the US Food and Drug Administration (FDA) for treating adults with stable disease in the maintenance phase of therapy [<a href="#rid43">43-45</a>]. Doses of trientine formulations are generally not equivalent (except if expressed as trientine base), and local product labeling should be consulted. </p><p>We advise patients to avoid taking <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a> with iron supplementation because trientine chelates iron and forms nephrotoxic complexes. If oral iron supplementation is needed, it may be given for a short course and with at least two-hour intervals between administration of trientine and iron.</p><p class="headingAnchor" id="H16"><span class="h4">Adverse effects</span><span class="headingEndMark"> — </span>Adverse effects related to <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a> use include pancytopenia (rare), colitis, hemorrhagic gastritis, loss of taste, rash, reversible sideroblastic anemia, and possibly hepatic iron overload with prolonged, high-dose therapy [<a href="#rid46">46-49</a>]. Excess iron may increase the risk of liver toxicity [<a href="#rid49">49</a>]. Overall, trientine seems to have fewer side effects than <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a>. Worsening of neurologic symptoms may occur with trientine [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H18"><span class="h4">Drug monitoring</span><span class="headingEndMark"> — </span>We measure complete blood count, urinalysis, and serum creatinine after the first week and then once a month during the first three months; then at three-month intervals until target urinary copper levels are achieved; and twice per year thereafter. (See <a class="local">'Assessing response to therapy'</a> below.) </p><p>We measure 24-hour urine for protein if urinalysis shows new or worsening proteinuria.</p><p class="headingAnchor" id="H19"><span class="h3">Zinc</span><span class="headingEndMark"> — </span>Oral zinc interferes with the absorption of copper by inducing enterocyte metallothionein (an endogenous chelator of metals), which has a greater affinity for copper than for zinc. Metallothionen binds luminal copper and thereby prevents it from entering into the circulation [<a href="#rid50">50</a>]. The bound copper is excreted in stool with normal turnover of enterocytes. Copper from salivary and gastric secretions is also bound, thereby further enhancing a negative copper balance [<a href="#rid51">51</a>]. Zinc may also induce hepatocellular metallothionein [<a href="#rid52">52,53</a>].</p><p class="headingAnchor" id="H20"><span class="h4">Dosing</span><span class="headingEndMark"> — </span>Zinc salts are available in several formulations that inhibit copper absorption similarly. However, the formulations differ in their absorption and tolerability. <a class="drug drug_general" data-topicid="9980" href="/z/d/drug information/9980.html" rel="external">Zinc acetate</a> has the best absorption. <a class="drug drug_general" data-topicid="96338" href="/z/d/drug information/96338.html" rel="external">Zinc gluconate</a> is an alternative, and it is more tolerable than <a class="drug drug_general" data-topicid="10328" href="/z/d/drug information/10328.html" rel="external">zinc sulfate</a> with respect to gastrointestinal side effects.  </p><p>Dosing is in milligrams of elemental zinc. The total daily dose of zinc for adults is 150 mg, given in three divided doses. Twice daily dosing is an alternative dosing regimen for patients who cannot adhere to three times daily dosing [<a href="#rid22">22</a>]. However, we do not use once daily dosing because it is not effective. </p><p>We advise patients to avoid eating for at least two hours before and for one hour after taking zinc because food interferes with zinc absorption.  </p><p class="headingAnchor" id="H22"><span class="h4">Adverse effects</span><span class="headingEndMark"> — </span>The most common adverse effect of zinc is gastric irritation leading to dyspepsia and/or gastritis. Approximately 30 percent of patients using zinc develop gastrointestinal side effects, and some patients require switching to an alternative zinc salt or to a chelating agent [<a href="#rid54">54</a>]. Uncommon adverse effects associated with zinc include worsening liver disease, worsening neurologic disease, and elevated serum amylase and lipase in the absence of acute pancreatitis [<a href="#rid18">18,55,56</a>].</p><p class="headingAnchor" id="H3413651230"><span class="h2">Assessing response to therapy</span><span class="headingEndMark"> — </span>We monitor response to initial therapy by measuring 24-hour urinary copper excretion and by assessing for clinical and biochemical improvement [<a href="#rid57">57</a>]. Most patients require at least six months of drug therapy to achieve these goals: </p><p class="bulletIndent1"><span class="glyph">●</span>Urinary copper excretion – We measure 24 urinary copper excretion within a month after achieving the goal dose of therapy. The pretreatment levels for urinary copper excretion may exceed 100 mcg/24 hours (1.6 micromol/24 hours) in symptomatic patients, and after initiating chelation (<a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> or <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a>), it may increase to above 1000 to 2000 mcg/24 hours (16 to 31 micromol/24 hours). The rate of copper excretion falls as copper stores become depleted. After 6 to 12 months of therapy, levels of urinary copper usually fall to below 500 mcg/24 hours (8 micromol/24 hours).</p><p></p><p class="bulletIndent1">For patients on zinc therapy, urinary copper begins to decline from pretreatment levels and should not exceed 100 mcg/24 hours (1.6 micromol/24 hours) over time. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Biochemical testing – We typically measure serum aminotransferases, total bilirubin and international normalized ratio (INR), every three months during treatment initiation, or more frequently in those with elevated pretreatment values. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms – We monitor patients for symptomatic improvement.</p><p></p><p>When target urinary copper levels are achieved, we reduce the frequency of measuring laboratory studies to every 6 to 12 months. (See <a class="local">'Monitoring during maintenance'</a> below.) </p><p>We transition patients who meet the following criteria to maintenance therapy (see <a class="local">'Patients who respond to drug therapy'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>For patients on <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> or <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a>, 24-hour urinary copper excretion &lt;500 mcg (8 micromol)/24 hours. For patients on zinc, 24-hour urinary copper excretion &lt;100 mcg (1.6 micromol)/24 hours </p><p class="bulletIndent1"><span class="glyph">●</span>Normal (or near normal) serum aminotransferases</p><p class="bulletIndent1"><span class="glyph">●</span>Symptomatic improvement</p><p></p><p class="headingAnchor" id="H3790228222"><span class="h1">SUBSEQUENT MANAGEMENT</span></p><p class="headingAnchor" id="H847213656"><span class="h2">Patients who respond to drug therapy</span></p><p class="headingAnchor" id="H1340433073"><span class="h3">Transitioning to maintenance therapy</span><span class="headingEndMark"> — </span>Patients with Wilson disease require lifelong therapy unless the patient undergoes liver transplantation [<a href="#rid12">12</a>] (see <a class="local">'Nonresponders'</a> below). The goals of maintenance therapy are to prevent copper from reaccumulating in tissue and to prevent progressive liver disease and acute liver injury.</p><p>Most patients require a minimum of 6 to 18 months of initial treatment to achieve disease remission. However, some patients may require up to five years of induction therapy. Prior to transitioning to maintenance therapy, patients should have symptomatic improvement, normal (or near normal) serum aminotransferases, and 24-hour urinary copper excretion within target ranges for their specific therapy (&lt;500 mcg [8 micromoles] per day for <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> or <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a>, and &lt;100 mcg [1.6 micromoles] per day for those on zinc). </p><p>Selecting maintenance therapy is informed by the patient's existing drug regimen, drug safety and efficacy, and patient preferences. Maintenance therapy options include either a lower dose chelating agent (ie, reducing the dose by approximately one-third) or zinc. For patients on a lower dose chelator, there is increasing use of <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a> for long-term maintenance because it has fewer side effects than <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a>. (See <a class="local">'Drug dosing and administration'</a> above.)</p><p>Data from randomized trials suggested that <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a> tetrahydrochloride was effective for preventing copper reaccumulation after initial chelation therapy. In an open-label trial including 53 patients with Wilson disease who were initially stabilized with <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a>, there were no significant differences in serum levels of non-ceruloplasmin-bound copper or in clinical response at 24 and 48 weeks for patients treated with trientine tetrahydrochloride compared with D-penicillamine [<a href="#rid45">45</a>]. In addition, trientine tetrahydrochloride was well tolerated with no serious adverse events.</p><p>Data from observational studies suggested that zinc salts were effective for maintaining copper balance [<a href="#rid54">54,58</a>]. In a study including 60 patients with Wilson disease who had achieved copper detoxification with a chelating agent, <a class="drug drug_general" data-topicid="9980" href="/z/d/drug information/9980.html" rel="external">zinc acetate</a> (50 mg dose three times daily) was associated with adequate copper balance in 64 patients (91 percent) [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H2470544743"><span class="h3">Monitoring during maintenance</span><span class="headingEndMark"> — </span>For patients on maintenance therapy, monitoring is important to detect loss of response or nonadherence before progressive liver disease develops. </p><p>For long-term monitoring, we perform a physical examination and measure the following every six months:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum copper</p><p class="bulletIndent1"><span class="glyph">●</span>Serum ceruloplasmin </p><p class="bulletIndent1"><span class="glyph">●</span>Liver biochemistries – Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)</p><p class="bulletIndent1"><span class="glyph">●</span>International normalized ratio (INR)</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count</p><p class="bulletIndent1"><span class="glyph">●</span>Urinalysis (for patients on <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> or <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a> therapy)</p><p></p><p>We also measure 24-hour urinary excretion of copper every 12 months or more frequently if we adjust the drug dose or suspect nonadherence. </p><p class="headingAnchor" id="H1722323854"><span class="h2">Nonresponders</span><span class="headingEndMark"> — </span>For patients who do not respond to initial therapy despite adhering to dietary and drug regimens in the absence of comorbid liver disease, other therapeutic options include [<a href="#rid59">59</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Combination therapy – For patients who do not respond or worsen with <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> or <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a> alone, adding zinc treatment along with the chelating agent (referred to as combination therapy) may be an option [<a href="#rid60">60</a>]. The complementary actions of zinc and chelating agents (preventing copper absorption and promoting copper removal, respectively) provide a physiologic rationale for using combination therapy. However, data from clinical trials are lacking. </p><p></p><p class="bulletIndent1">We instruct patients on combination therapy to take zinc at least twice daily and several hours apart from <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a>. The combination of zinc with D-penicillamine or <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a> may increase the risk for developing sideroblastic anemia if used chronically as it may lead to more copper depletion (ie, overtreatment). Thus, we monitor hemoglobin levels every three to six months along with monitoring liver biochemistries. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver transplantation – Indications for liver transplantation in patients with Wilson disease include acute liver failure, decompensated cirrhosis unresponsive to drug therapy, and cirrhosis complicated by hepatocellular carcinoma [<a href="#rid61">61,62</a>]. (See  <a class="medical medical_review" href="/z/d/html/2490.html" rel="external">"Liver transplantation for hepatocellular carcinoma"</a> and <a class="local">'Special populations'</a> below.)</p><p></p><p class="bulletIndent1">Liver transplantation cures Wilson disease; thus, patients do not resume therapy for Wilson disease after transplantation. In addition, long-term outcomes following liver transplantation for Wilson disease are excellent [<a href="#rid62">62-64</a>]. In a series of 27 adults with Wilson disease who underwent liver transplantation, one- and five-year patient survival rates were 88 and 83 percent, respectively [<a href="#rid62">62</a>]. In an earlier database study including 170 children and 400 adults with Wilson disease who received a liver transplant, there were no significant differences in pediatric compared with adult patient survival rates (one-year survival: 90 versus 88 percent, and five-year survival: 89 versus 86 percent) [<a href="#rid63">63</a>]. (See <a class="local">'Pediatric patients'</a> below.)</p><p></p><p class="bulletIndent1">Whether liver transplantation is indicated for treating neurologic Wilson disease is uncertain [<a href="#rid11">11,65-68</a>]. Although data from case series suggested that liver transplantation was associated with some neurologic improvement, patients with persistent neuropsychiatric disease may have difficulty adhering to lifelong immunosuppression. In addition, patient survival rates may be lower in patients with neurologic involvement. In an observational study including 18 patients with Wilson disease who underwent liver transplantation for severe neurologic symptoms (eg, dystonia, parkinsonism), patient survival rates at one, three, and five years were 88, 72, and 72 percent, respectively [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Investigational agents – Another chelating agent, ammonium tetrathiomolybdate (TTM), interferes with copper absorption when the medication is given orally with meals, and binds plasma copper [<a href="#rid69">69,70</a>]. Preliminary data suggested that ammonium TTM improved neurologic symptoms with a lower risk of worsening neurologic symptoms compared with <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a> [<a href="#rid71">71</a>]. However, clinical trials involving an alternative, stabilized form of TTM were halted, and neither formulation is commercially available [<a href="#rid72">72</a>].</p><p></p><p class="headingAnchor" id="H4102122045"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The prognosis in patients with Wilson disease who adhere to lifelong therapy is generally good. The natural history, overall survival, and risk of hepatocellular carcinoma in patients with Wilson disease are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/83837.html" rel="external">"Wilson disease: Clinical manifestations, diagnosis, and natural history", section on 'Disease course'</a>.) </p><p class="headingAnchor" id="H355935792"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H27"><span class="h2">Patients with acute liver failure</span><span class="headingEndMark"> — </span>We evaluate patients with acute liver failure related to Wilson disease for urgent liver transplantation, and we manage such patients at a liver transplant center. General measures for patients with acute liver failure, including monitoring and nutritional support, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3570.html" rel="external">"Acute liver failure in adults: Management and prognosis", section on 'General management'</a>.)</p><p>Patients with acute liver failure often require liver transplantation. The goal of initial therapy is removing copper rapidly and stabilizing the patient while awaiting transplantation for definitive treatment. Several interventions are available for removing copper rapidly, including apheresis and renal replacement therapy [<a href="#rid73">73</a>]. Net copper removal is proportional to plasma concentration and can reach 12 mg per session. In addition, most patients with acute liver failure related to Wilson disease have hemolytic anemia. Copper ions leak from necrotic hepatocytes into the circulation and cause lysis of red blood cells. Therapies to reduce hemolysis and prevent kidney injury related to copper and copper complexes include plasmapheresis, plasma exchange, renal replacement therapy, and use of a molecular absorbant recirculating system (MARS) device [<a href="#rid74">74-78</a>]. </p><p>The clinical presentation of acute liver failure related to Wilson disease is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/83837.html" rel="external">"Wilson disease: Clinical manifestations, diagnosis, and natural history", section on 'Liver disease'</a>.)</p><p class="headingAnchor" id="H749701764"><span class="h2">Patients with cirrhosis</span><span class="headingEndMark"> — </span>Patients with cirrhosis may experience improvement of liver disease with chelating therapy, and these clinical improvements (eg, resolution of ascites, fibrosis regression, and reduction in liver stiffness measured by elastography) may occur beyond six months of initiating treatment. </p><p>Some patients with cirrhosis and portal hypertension have leukopenia and thrombocytopenia at baseline. Thus, if <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> is initiated, we monitor complete blood count every month at first, then two to four times per year afterwards. We discontinue D-penicillamine for patients with cirrhosis who develop leukopenia (white blood cell count &lt;3000/microL), neutropenia (neutrophil count &lt;2000/microL), or thrombocytopenia (platelet count &lt;30,000/microL). (See <a class="local">'D-penicillamine'</a> above.)</p><p>General measures for patients with cirrhosis including management of complications (eg, hepatic encephalopathy) are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis"</a>.)</p><p class="headingAnchor" id="H1120108806"><span class="h2">Pregnancy and lactation</span><span class="headingEndMark"> — </span>We continue drug therapy for Wilson disease during pregnancy because stopping therapy has been associated with risk of acute liver failure, clinical deterioration, and maternal mortality [<a href="#rid79">79</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjusting drug therapy</strong> – Adjusting drug therapy during pregnancy is informed by the relative drug safety, risks of interrupting therapy, clinical experience, available data, and society guidelines [<a href="#rid21">21</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> – We continue D-penicillamine during pregnancy because it is generally safe. However, D-penicillamine has rarely been associated with cutaneous and thyroid abnormalities in the offspring of mothers exposed to the drug during pregnancy [<a href="#rid80">80,81</a>]. </p><p></p><p class="bulletIndent2">We typically lower the <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> dose by 25 to 50 percent of the pre-pregnancy dose to reduce risk to the fetus during the first trimester and to promote better wound healing for mothers who have a cesarean delivery or episiotomy. We monitor patient symptoms and measure liver biochemistries once during each trimester to confirm that the patient is tolerating dose adjustment. We continue the lower maintenance dose for two to three weeks after delivery, and then resume the pre-pregnancy dose. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">Trientine</a> – We continue trientine during pregnancy based on clinical experience, although published data on the safety of trientine during pregnancy are limited. We typically lower the trientine dose by 25 to 50 percent of the pre-pregnancy dose. We monitor patient symptoms and measure liver biochemistries once during each trimester to confirm that the patient is tolerating dose adjustment. We continue the lower maintenance dose for two to three weeks after delivery, and then resume the pre-pregnancy dose. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Zinc – We continue zinc during pregnancy without dose adjustment. Studies in pregnant patients suggested that zinc salts were not associated with increased risk of fetal abnormalities [<a href="#rid82">82</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lactation – </strong><a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> is excreted in mother's milk, whereas it is unknown whether the <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a> is excreted in mother's milk [<a href="#rid83">83</a>]. In addition, the human milk concentration of copper may be reduced in patients with Wilson disease [<a href="#rid83">83,84</a>]. Thus, the amount of copper in mother's milk may be inadequate to meet the daily requirements of the developing newborn. We advise mothers to discuss the possible risks related to lactation with their newborn's clinician who may monitor the newborn for copper deficiency. (See  <a class="medical medical_review" href="/z/d/html/5359.html" rel="external">"Laboratory and radiologic evaluation of nutritional status in children", section on 'Minerals'</a>.)</p><p></p><p class="headingAnchor" id="H1799255927"><span class="h2">Patients undergoing elective surgery</span><span class="headingEndMark"> — </span>We continue drug therapy for patients with Wilson disease who are undergoing elective surgery because stopping therapy has been associated with acute liver failure and liver decompensation. (See <a class="local">'Pregnancy and lactation'</a> above.)</p><p>For patients on chelating therapy, we typically lower the dose by 25 to 50 percent prior to surgery because chelating agents have been associated with impaired wound healing [<a href="#rid21">21</a>]. We resume the pre-surgery dose after surgical wounds have healed.</p><p class="headingAnchor" id="H2009323112"><span class="h2">Pediatric patients</span><span class="headingEndMark"> — </span>We provide nutritional counseling for pediatric patients and their caregivers. Copper and zinc are required for the metabolic and developmental needs of pediatric patients. In addition, we monitor copper dietary intake (eg, infant formula, solid foods) to avoid excess copper exposure. </p><p>Drug dosing for pediatric patients is generally informed by patient age and/or weight:</p><p class="bulletIndent1"><span class="glyph">●</span>Age &lt;5 years – There is no consensus on optimal timing for initiating drug therapy for young children with Wilson disease [<a href="#rid25">25</a>]. Factors informing the decision include patient symptoms and liver biochemistries, potential adverse effects of drug therapy (eg, copper deficiency), and patient/caregiver preferences. When drug therapy is indicated for pediatric patients &lt;5 years of age, we typically use zinc. The total daily dose of zinc is 50 mg, given in two divided doses, although published data on the optimal dose for younger children are lacking [<a href="#rid85">85</a>]. </p><p></p><p class="bulletIndent1">Other challenges to initiating drug therapy in very young children include risk of copper deficiency with therapy and lack of 24-hour urinary copper monitoring to guide therapy (ie, patients are not yet toilet trained) [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age ≥5 years – Weight-based dose adjustments for <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> and <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a> are discussed above. (See <a class="local">'D-penicillamine'</a> above and <a class="local">'Trientine'</a> above.)</p><p></p><p class="bulletIndent1">For older pediatric patients weighing ≥50 kg, the total daily dose of zinc is 150 mg, given in three divided doses. Twice daily dosing is an alternative dosing regimen for patients who cannot adhere to three times daily dosing [<a href="#rid22">22</a>]. For older pediatric patients who weigh &lt;50 kg, the total daily dose is 75 mg, given in three divided doses [<a href="#rid85">85</a>].</p><p></p><p>For pediatric patients, elevated serum aminotransferases do not necessarily indicate nonadherence because up to one-third of pediatric patients continue to have mildly elevated aminotransferases despite adequate treatment [<a href="#rid87">87</a>]. However, for patients in whom the aminotransferases normalized with therapy, new elevations in liver biochemistries warrant further investigation. </p><p class="headingAnchor" id="H1747447123"><span class="h2">Patients with neuropsychiatric symptoms</span><span class="headingEndMark"> — </span>For patients with neuropsychiatric symptoms (eg, tremor, dystonia), restoring normal copper balance with drug therapy typically results in symptomatic improvement. However, some patients may require additional therapies (eg, pharmacologic, physical, and/or speech therapy) to alleviate neuropsychiatric symptoms [<a href="#rid88">88-90</a>]. </p><p>Management of specific neurologic and psychiatric conditions is discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Chorea – (See  <a class="medical medical_review" href="/z/d/html/14133.html" rel="external">"Overview of chorea", section on 'Management of chorea'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dystonia – (See  <a class="medical medical_review" href="/z/d/html/4887.html" rel="external">"Treatment of dystonia in children and adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gait abnormalities/ataxia – (See  <a class="medical medical_review" href="/z/d/html/14134.html" rel="external">"Overview of cerebellar ataxia in adults", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Parkinsonism – (See  <a class="medical medical_review" href="/z/d/html/4899.html" rel="external">"Nonpharmacologic management of Parkinson disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tremor – (See  <a class="medical medical_review" href="/z/d/html/4895.html" rel="external">"Overview of tremor", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Seizures – (See  <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6203.html" rel="external">"Seizures and epilepsy in children: Initial treatment and monitoring"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bipolar disorder – (See  <a class="medical medical_review" href="/z/d/html/15267.html" rel="external">"Bipolar major depression in adults: Choosing treatment"</a> and  <a class="medical medical_review" href="/z/d/html/15925.html" rel="external">"Pediatric bipolar disorder: Overview of choosing treatment"</a>.)</p><p></p><p class="headingAnchor" id="H307522736"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116713.html" rel="external">"Society guideline links: Inherited liver disease"</a>.)</p><p class="headingAnchor" id="H31"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General measures</strong> – General measures for all patients with Wilson disease include (see <a class="local">'General measures'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Avoiding foods with high copper content. A list of food mineral content is available on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffdc.nal.usda.gov%2F&amp;token=YRvsg6S0dX25uLS7m4P5uJEU7qlTdokoB336745NsmgxbU0Ad45yx1WsPc86EH7R&amp;TOPIC_ID=3591" target="_blank">United States Department of Agriculture website</a>. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age-appropriate immunizations, in addition to vaccination for hepatitis A virus and hepatitis B virus for patients without serologic evidence of immunity. (See  <a class="medical medical_review" href="/z/d/html/3891.html" rel="external">"Immunizations for adults with chronic liver disease"</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We advise patients to refrain from alcohol and, in particular, avoid heavy alcohol use (ie, &gt;14 drinks per week or &gt;4 drinks on a given day for males and &gt;7 drinks per week or &gt;3 drinks on a given day for females).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hepatology consultation for long-term management.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of therapy</strong> – Goals of therapy are to detoxify excess copper in tissue, prevent copper from further accumulation in tissue, improve symptoms, and improve liver function. (See <a class="local">'Treatment goals'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment testing</strong> – Prior to initiating pharmacologic therapy, we obtain or review the following studies (see <a class="local">'Pretreatment evaluation'</a> above) :  </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>24-hour urinary copper excretion</p><p class="bulletIndent2"><span class="glyph">•</span>Ceruloplasmin</p><p class="bulletIndent2"><span class="glyph">•</span>International normalized ratio (INR)</p><p class="bulletIndent2"><span class="glyph">•</span>Iron studies and ferritin</p><p class="bulletIndent2"><span class="glyph">•</span>Serum aminotransferases – Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)</p><p class="bulletIndent2"><span class="glyph">•</span>Serum copper</p><p class="bulletIndent2"><span class="glyph">•</span>Serum creatinine</p><p class="bulletIndent2"><span class="glyph">•</span>Serum sodium</p><p class="bulletIndent2"><span class="glyph">•</span>Total bilirubin</p><p class="bulletIndent2"><span class="glyph">•</span>Uric acid</p><p class="bulletIndent2"><span class="glyph">•</span>Urinalysis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial therapy </strong>–<strong> </strong>Selecting an initial therapy is informed by whether the patient has symptoms and/or evidence of organ damage related to copper accumulation  (<a class="graphic graphic_algorithm graphicRef142796" href="/z/d/graphic/142796.html" rel="external">algorithm 1</a>) (see <a class="local">'Selecting initial therapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with symptoms and/or organ damage – For patients with symptoms and/or organ damage, we suggest initial therapy with a <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> rather than <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a> or oral zinc (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Observational data and clinical experience suggested that D-penicillamine was effective for improving symptoms and liver function in addition to preventing disease progression. Trientine is a reasonable option for initial therapy, whereas zinc may be less effective. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Asymptomatic patients without organ damage – For patients without symptoms or organ damage, we use drug therapy rather than expectant management (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Drug therapy prevents additional copper from accumulating in tissues and prevents the development of symptoms. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance therapy</strong> – Criteria for transitioning to maintenance therapy include symptomatic improvement, normal (or near normal) serum aminotransferases, and 24-hour urinary copper excretion &lt;500 mcg (8 micromoles)/24 hours for patients on <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> or <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a>, and &lt;100 mcg (1.6 micromol)/24 hours for patients on zinc. (See <a class="local">'Subsequent management'</a> above.)</p><p></p><p class="bulletIndent1">Patients require maintenance drug therapy indefinitely. Discontinuing therapy may lead to acute liver failure and/or progressive liver disease. Selecting maintenance therapy is informed by the patient's existing drug regimen, drug safety and efficacy, and patient preferences. Maintenance therapy options include either a lower dose chelating agent (ie, reducing the dose by approximately one-third) or zinc.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Special populations</strong> – Some patients develop complications or have other indications for modifying therapy. A discussion of these special populations includes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with acute liver failure – (See <a class="local">'Patients with acute liver failure'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with cirrhosis – (See <a class="local">'Patients with cirrhosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pregnancy and lactation – (See <a class="local">'Pregnancy and lactation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients undergoing elective surgery – (See <a class="local">'Patients undergoing elective surgery'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pediatric patients – (See <a class="local">'Pediatric patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with neuropsychiatric symptoms – (See <a class="local">'Patients with neuropsychiatric symptoms'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wilson DM, Goldstein NP. Renal urate excretion in patients with Wilson's disease. Kidney Int 1973; 4:331.</a></li><li class="breakAll">https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/alcohol-facts-and-statistics (Accessed on December 26, 2022).</li><li><a class="nounderline abstract_t">Seetharaman J, Sarma MS. Chelation therapy in liver diseases of childhood: Current status and response. World J Hepatol 2021; 13:1552.</a></li><li><a class="nounderline abstract_t">Lau JY, Lai CL, Wu PC, et al. Wilson's disease: 35 years' experience. Q J Med 1990; 75:597.</a></li><li><a class="nounderline abstract_t">Falkmer S, Samuelson G, Sjölin S. Penicillamine-induced normalization of clinical signs, and liver morphology and histochemistry in a case of Wilson's disease. Pediatrics 1970; 45:260.</a></li><li><a class="nounderline abstract_t">Walshe JM. Copper chelation in patients with Wilson's disease. A comparison of penicillamine and triethylene tetramine dihydrochloride. Q J Med 1973; 42:441.</a></li><li><a class="nounderline abstract_t">Sass-Kortsak A. Wilson's disease. A treatable liver disease in children. Pediatr Clin North Am 1975; 22:963.</a></li><li><a class="nounderline abstract_t">Grand RJ, Vawter GF. Juvenile Wilson disease: histologic and functional studies during penicillamine therapy. J Pediatr 1975; 87:1161.</a></li><li><a class="nounderline abstract_t">Sternlieb I. Copper and the liver. Gastroenterology 1980; 78:1615.</a></li><li><a class="nounderline abstract_t">Czlonkowska A, Gajda J, Rodo M. Effects of long-term treatment in Wilson's disease with D-penicillamine and zinc sulphate. J Neurol 1996; 243:269.</a></li><li><a class="nounderline abstract_t">Weiss KH, Thurik F, Gotthardt DN, et al. Efficacy and safety of oral chelators in treatment of patients with Wilson disease. Clin Gastroenterol Hepatol 2013; 11:1028.</a></li><li><a class="nounderline abstract_t">Scheinberg IH, Jaffe ME, Sternlieb I. The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease. N Engl J Med 1987; 317:209.</a></li><li><a class="nounderline abstract_t">Walshe JM. The management of Wilson's disease with trienthylene tetramine 2HC1 (Trien 2HC1). Prog Clin Biol Res 1979; 34:271.</a></li><li><a class="nounderline abstract_t">Saito H, Watanabe K, Sahara M, et al. Triethylene-tetramine (trien) therapy for Wilson's disease. Tohoku J Exp Med 1991; 164:29.</a></li><li><a class="nounderline abstract_t">Dubois RS, Rodgerson DO, Hambidge KM. Treatment of Wilson's disease with triethylene tetramine hydrochloride (Trientine). J Pediatr Gastroenterol Nutr 1990; 10:77.</a></li><li><a class="nounderline abstract_t">Wiggelinkhuizen M, Tilanus ME, Bollen CW, Houwen RH. Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease. Aliment Pharmacol Ther 2009; 29:947.</a></li><li><a class="nounderline abstract_t">Linn FH, Houwen RH, van Hattum J, et al. Long-term exclusive zinc monotherapy in symptomatic Wilson disease: experience in 17 patients. Hepatology 2009; 50:1442.</a></li><li><a class="nounderline abstract_t">Weiss KH, Gotthardt DN, Klemm D, et al. Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease. Gastroenterology 2011; 140:1189.</a></li><li class="breakAll">Trientine hydrochloride capsule. United States Prescribing Information. U.S. National Library of Medicine. Revised September 2020. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c34f77a7-996b-4470-b5df-d946a7fe5dbe (Accessed on March 03, 2023).</li><li><a class="nounderline abstract_t">Brewer GJ, Yuzbasiyan-Gurkan V, Lee DY, Appelman H. Treatment of Wilson's disease with zinc. VI. Initial treatment studies. J Lab Clin Med 1989; 114:633.</a></li><li><a class="nounderline abstract_t">Schilsky ML, Roberts EA, Bronstein JM, et al. A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases. Hepatology 2022.</a></li><li><a class="nounderline abstract_t">Brewer GJ, Dick RD, Johnson VD, et al. Treatment of Wilson's disease with zinc: XV long-term follow-up studies. J Lab Clin Med 1998; 132:264.</a></li><li><a class="nounderline abstract_t">Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, et al. Treatment of Wilson's disease with zinc. XIII: Therapy with zinc in presymptomatic patients from the time of diagnosis. J Lab Clin Med 1994; 123:849.</a></li><li><a class="nounderline abstract_t">Marcellini M, Di Ciommo V, Callea F, et al. Treatment of Wilson's disease with zinc from the time of diagnosis in pediatric patients: a single-hospital, 10-year follow-up study. J Lab Clin Med 2005; 145:139.</a></li><li><a class="nounderline abstract_t">Valentino PL, Roberts EA, Beer S, et al. Management of Wilson Disease Diagnosed in Infancy: An Appraisal of Available Experience to Generate Discussion. J Pediatr Gastroenterol Nutr 2020; 70:547.</a></li><li><a class="nounderline abstract_t">Mizuochi T, Kimura A, Shimizu N, et al. Zinc monotherapy from time of diagnosis for young pediatric patients with presymptomatic Wilson disease. J Pediatr Gastroenterol Nutr 2011; 53:365.</a></li><li><a class="nounderline abstract_t">Roberts EA, Schilsky ML, Division of Gastroenterology and Nutrition, Hospital for Sick Children, Toronto, Ontario, Canada. A practice guideline on Wilson disease. Hepatology 2003; 37:1475.</a></li><li><a class="nounderline abstract_t">Kukovetz WR, Beubler E, Kreuzig F, et al. Bioavailability and pharmacokinetics of D-penicillamine. J Rheumatol 1983; 10:90.</a></li><li><a class="nounderline abstract_t">Medici V, Trevisan CP, D'Incà R, et al. Diagnosis and management of Wilson's disease: results of a single center experience. J Clin Gastroenterol 2006; 40:936.</a></li><li><a class="nounderline abstract_t">Litwin T, Dzieżyc K, Karliński M, et al. Early neurological worsening in patients with Wilson's disease. J Neurol Sci 2015; 355:162.</a></li><li><a class="nounderline abstract_t">Merle U, Schaefer M, Ferenci P, Stremmel W. Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study. Gut 2007; 56:115.</a></li><li><a class="nounderline abstract_t">Mohr I, Pfeiffenberger J, Eker E, et al. Neurological worsening in Wilson disease - clinical classification and outcome. J Hepatol 2023; 79:321.</a></li><li><a class="nounderline abstract_t">Habib GS, Saliba W, Nashashibi M, Armali Z. Penicillamine and nephrotic syndrome. Eur J Intern Med 2006; 17:343.</a></li><li><a class="nounderline abstract_t">Hall CL, Jawad S, Harrison PR, et al. Natural course of penicillamine nephropathy: a long term study of 33 patients. Br Med J (Clin Res Ed) 1988; 296:1083.</a></li><li><a class="nounderline abstract_t">Bécuwe C, Dalle S, Ronger-Savlé S, et al. Elastosis perforans serpiginosa associated with pseudo-pseudoxanthoma elasticum during treatment of Wilson's disease with penicillamine. Dermatology 2005; 210:60.</a></li><li><a class="nounderline abstract_t">Hill VA, Seymour CA, Mortimer PS. Pencillamine-induced elastosis perforans serpiginosa and cutis laxa in Wilson's disease. Br J Dermatol 2000; 142:560.</a></li><li><a class="nounderline abstract_t">Deguti MM, Mucenic M, Cancado EL, Tietge UJ. Elastosis perforans serpiginosa secondary to D-penicillamine treatment in a Wilson's disease patient. Am J Gastroenterol 2002; 97:2153.</a></li><li><a class="nounderline abstract_t">Popadic S, Skiljevic D, Medenica L. Bullous pemphigoid induced by penicillamine in a patient with Wilson disease. Am J Clin Dermatol 2009; 10:36.</a></li><li><a class="nounderline abstract_t">Shiono Y, Wakusawa S, Hayashi H, et al. Iron accumulation in the liver of male patients with Wilson's disease. Am J Gastroenterol 2001; 96:3147.</a></li><li class="breakAll">Trientine hydrochloride. https://chem.nlm.nih.gov/chemidplus/name/startswith/triethylene%20tetramine%20dihydrochloride (Accessed on June 26, 2022).</li><li><a class="nounderline abstract_t">Kodama H, Murata Y, Iitsuka T, Abe T. Metabolism of administered triethylene tetramine dihydrochloride in humans. Life Sci 1997; 61:899.</a></li><li><a class="nounderline abstract_t">Ala A, Aliu E, Schilsky ML. Prospective pilot study of a single daily dosage of trientine for the treatment of Wilson disease. Dig Dis Sci 2015; 60:1433.</a></li><li class="breakAll">Trientine tetrahydrochloride. US Food &amp; Drug Administration (FDA) approved product information. Revised April 2022. Available online https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215760s000lbl.pdf (Accessed on June 08, 2022).</li><li class="breakAll">Trientine tetrahydrochloride. US Food &amp;Drug Administration approval letter. April 28, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/215760Orig1s000ltr.pdf (Accessed on June 26, 2022).</li><li><a class="nounderline abstract_t">Schilsky ML, Czlonkowska A, Zuin M, et al. Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol 2022; 7:1092.</a></li><li><a class="nounderline abstract_t">Perry AR, Pagliuca A, Fitzsimons EJ, et al. Acquired sideroblastic anaemia induced by a copper-chelating agent. Int J Hematol 1996; 64:69.</a></li><li><a class="nounderline abstract_t">Condamine L, Hermine O, Alvin P, et al. Acquired sideroblastic anaemia during treatment of Wilson's disease with triethylene tetramine dihydrochloride. Br J Haematol 1993; 83:166.</a></li><li><a class="nounderline abstract_t">Dahlman T, Hartvig P, Löfholm M, et al. Long-term treatment of Wilson's disease with triethylene tetramine dihydrochloride (trientine). QJM 1995; 88:609.</a></li><li><a class="nounderline abstract_t">Shiono Y, Hayashi H, Wakusawa S, Yano M. Ultrastructural identification of iron and copper accumulation in the liver of a male patient with Wilson disease. Med Electron Microsc 2001; 34:54.</a></li><li><a class="nounderline abstract_t">Sturniolo GC, Mestriner C, Irato P, et al. Zinc therapy increases duodenal concentrations of metallothionein and iron in Wilson's disease patients. Am J Gastroenterol 1999; 94:334.</a></li><li><a class="nounderline abstract_t">Brewer GJ, Hill GM, Prasad AS, et al. Oral zinc therapy for Wilson's disease. Ann Intern Med 1983; 99:314.</a></li><li><a class="nounderline abstract_t">Schilsky ML, Blank RR, Czaja MJ, et al. Hepatocellular copper toxicity and its attenuation by zinc. J Clin Invest 1989; 84:1562.</a></li><li><a class="nounderline abstract_t">Cousins RJ. Absorption, transport, and hepatic metabolism of copper and zinc: special reference to metallothionein and ceruloplasmin. Physiol Rev 1985; 65:238.</a></li><li><a class="nounderline abstract_t">Camarata MA, Ala A, Schilsky ML. Zinc Maintenance Therapy for Wilson Disease: A Comparison Between Zinc Acetate and Alternative Zinc Preparations. Hepatol Commun 2019; 3:1151.</a></li><li><a class="nounderline abstract_t">Walshe JM, Munro NA. Zinc-induced deterioration in Wilson's disease aborted by treatment with penicillamine, dimercaprol, and a novel zero copper diet. Arch Neurol 1995; 52:10.</a></li><li><a class="nounderline abstract_t">Lang CJ, Rabas-Kolominsky P, Engelhardt A, et al. Fatal deterioration of Wilson's disease after institution of oral zinc therapy. Arch Neurol 1993; 50:1007.</a></li><li><a class="nounderline abstract_t">Roberts EA, Schilsky ML. Current and Emerging Issues in Wilson's Disease. N Engl J Med 2023; 389:922.</a></li><li class="breakAll">Zinc acetate. United States Prescribing Information. Revised July, 2020. US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0c72bff-20f3-4241-b966-34a95178d1a3 (Accessed on March 20, 2023).</li><li><a class="nounderline abstract_t">Wong RJ, Gish R, Schilsky M, Frenette C. A clinical assessment of Wilson disease in patients with concurrent liver disease. J Clin Gastroenterol 2011; 45:267.</a></li><li><a class="nounderline abstract_t">Askari FK, Greenson J, Dick RD, et al. Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. J Lab Clin Med 2003; 142:385.</a></li><li><a class="nounderline abstract_t">Emre S, Atillasoy EO, Ozdemir S, et al. Orthotopic liver transplantation for Wilson's disease: a single-center experience. Transplantation 2001; 72:1232.</a></li><li><a class="nounderline abstract_t">Ferrarese A, Morelli MC, Carrai P, et al. Outcomes of Liver Transplant for Adults With Wilson's Disease. Liver Transpl 2020; 26:507.</a></li><li><a class="nounderline abstract_t">Arnon R, Annunziato R, Schilsky M, et al. Liver transplantation for children with Wilson disease: comparison of outcomes between children and adults. Clin Transplant 2011; 25:E52.</a></li><li><a class="nounderline abstract_t">Guillaud O, Dumortier J, Sobesky R, et al. Long term results of liver transplantation for Wilson's disease: experience in France. J Hepatol 2014; 60:579.</a></li><li><a class="nounderline abstract_t">Poujois A, Sobesky R, Meissner WG, et al. Liver transplantation as a rescue therapy for severe neurologic forms of Wilson disease. Neurology 2020; 94:e2189.</a></li><li><a class="nounderline abstract_t">Bandmann O, Weiss KH, Hedera P. Liver transplant for neurologic Wilson disease: Hope or fallacy? Neurology 2020; 94:907.</a></li><li><a class="nounderline abstract_t">Medici V, Mirante VG, Fassati LR, et al. Liver transplantation for Wilson's disease: The burden of neurological and psychiatric disorders. Liver Transpl 2005; 11:1056.</a></li><li><a class="nounderline abstract_t">Stracciari A, Tempestini A, Borghi A, Guarino M. Effect of liver transplantation on neurological manifestations in Wilson disease. Arch Neurol 2000; 57:384.</a></li><li><a class="nounderline abstract_t">Brewer GJ, Dick RD, Johnson V, et al. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients. Arch Neurol 1994; 51:545.</a></li><li><a class="nounderline abstract_t">Brewer GJ, Hedera P, Kluin KJ, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 2003; 60:379.</a></li><li><a class="nounderline abstract_t">Brewer GJ, Askari F, Lorincz MT, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 2006; 63:521.</a></li><li class="breakAll">https://clinicaltrials.gov/ct2/show/NCT02273596?term=WTx101&amp;rank=1%20or%20https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001703-41/DE#G.</li><li><a class="nounderline abstract_t">Proost R, Cassiman D, Levtchenko E, et al. Fulminant Wilson Disease in Children: Recovery After Plasma Exchange Without Transplantation. J Pediatr Gastroenterol Nutr 2020; 71:720.</a></li><li><a class="nounderline abstract_t">Sen S, Mookerjee RP, Davies NA, et al. Review article: the molecular adsorbents recirculating system (MARS) in liver failure. Aliment Pharmacol Ther 2002; 16 Suppl 5:32.</a></li><li><a class="nounderline abstract_t">Rustom N, Bost M, Cour-Andlauer F, et al. Effect of molecular adsorbents recirculating system treatment in children with acute liver failure caused by Wilson disease. J Pediatr Gastroenterol Nutr 2014; 58:160.</a></li><li><a class="nounderline abstract_t">Jhang JS, Schilsky ML, Lefkowitch JH, Schwartz J. Therapeutic plasmapheresis as a bridge to liver transplantation in fulminant Wilson disease. J Clin Apher 2007; 22:10.</a></li><li><a class="nounderline abstract_t">Collins KL, Roberts EA, Adeli K, et al. Single pass albumin dialysis (SPAD) in fulminant Wilsonian liver failure: a case report. Pediatr Nephrol 2008; 23:1013.</a></li><li><a class="nounderline abstract_t">Sukezaki A, Chu PS, Shinoda M, et al. Late-onset acute liver failure due to Wilson's disease managed by plasmapheresis and hemodiafiltration successfully serving as a bridge for deceased donor liver transplantation: a case report and literature review. Clin J Gastroenterol 2020; 13:1239.</a></li><li><a class="nounderline abstract_t">Pfeiffenberger J, Beinhardt S, Gotthardt DN, et al. Pregnancy in Wilson's disease: Management and outcome. Hepatology 2018; 67:1261.</a></li><li><a class="nounderline abstract_t">Pinter R, Hogge WA, McPherson E. Infant with severe penicillamine embryopathy born to a woman with Wilson disease. Am J Med Genet A 2004; 128A:294.</a></li><li><a class="nounderline abstract_t">Hanukoglu A, Curiel B, Berkowitz D, et al. Hypothyroidism and dyshormonogenesis induced by D-penicillamine in children with Wilson's disease and healthy infants born to a mother with Wilson's disease. J Pediatr 2008; 153:864.</a></li><li><a class="nounderline abstract_t">Brewer GJ, Johnson VD, Dick RD, et al. Treatment of Wilson's disease with zinc. XVII: treatment during pregnancy. Hepatology 2000; 31:364.</a></li><li><a class="nounderline abstract_t">Sternlieb I. Wilson's disease and pregnancy. Hepatology 2000; 31:531.</a></li><li><a class="nounderline abstract_t">Michalczyk A, Bastow E, Greenough M, et al. ATP7B expression in human breast epithelial cells is mediated by lactational hormones. J Histochem Cytochem 2008; 56:389.</a></li><li><a class="nounderline abstract_t">Brewer GJ, Dick RD, Johnson VD, et al. Treatment of Wilson's disease with zinc XVI: treatment during the pediatric years. J Lab Clin Med 2001; 137:191.</a></li><li><a class="nounderline abstract_t">Nicastro E, Ranucci G, Vajro P, et al. Re-evaluation of the diagnostic criteria for Wilson disease in children with mild liver disease. Hepatology 2010; 52:1948.</a></li><li><a class="nounderline abstract_t">Iorio R, D'Ambrosi M, Marcellini M, et al. Serum transaminases in children with Wilson's disease. J Pediatr Gastroenterol Nutr 2004; 39:331.</a></li><li><a class="nounderline abstract_t">Srinivas K, Sinha S, Taly AB, et al. Dominant psychiatric manifestations in Wilson's disease: a diagnostic and therapeutic challenge! J Neurol Sci 2008; 266:104.</a></li><li><a class="nounderline abstract_t">Zimbrean P, Seniów J. Cognitive and psychiatric symptoms in Wilson disease. Handb Clin Neurol 2017; 142:121.</a></li><li><a class="nounderline abstract_t">Zimbrean PC, Schilsky ML. The spectrum of psychiatric symptoms in Wilson's disease: treatment and prognostic considerations. Am J Psychiatry 2015; 172:1068.</a></li></ol></div><div id="topicVersionRevision">Topic 3591 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4762580" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Renal urate excretion in patients with Wilson's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4762580" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Renal urate excretion in patients with Wilson's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34904029" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Chelation therapy in liver diseases of childhood: Current status and response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2217665" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Wilson's disease: 35 years' experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5413388" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Penicillamine-induced normalization of clinical signs, and liver morphology and histochemistry in a case of Wilson's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4728043" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Copper chelation in patients with Wilson's disease. A comparison of penicillamine and triethylene tetramine dihydrochloride.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1105368" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Wilson's disease. A treatable liver disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1185415" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Juvenile Wilson disease: histologic and functional studies during penicillamine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6245986" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Copper and the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8936358" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Effects of long-term treatment in Wilson's disease with D-penicillamine and zinc sulphate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23542331" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Efficacy and safety of oral chelators in treatment of patients with Wilson disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3600712" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/531055" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The management of Wilson's disease with trienthylene tetramine 2HC1 (Trien 2HC1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1926144" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Triethylene-tetramine (trien) therapy for Wilson's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2324883" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatment of Wilson's disease with triethylene tetramine hydrochloride (Trientine).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19210288" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19731238" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Long-term exclusive zinc monotherapy in symptomatic Wilson disease: experience in 17 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21185835" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21185835" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2592853" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Treatment of Wilson's disease with zinc. VI. Initial treatment studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36151586" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9794697" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Treatment of Wilson's disease with zinc: XV long-term follow-up studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8201263" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Treatment of Wilson's disease with zinc. XIII: Therapy with zinc in presymptomatic patients from the time of diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15871305" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Treatment of Wilson's disease with zinc from the time of diagnosis in pediatric patients: a single-hospital, 10-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31899725" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Management of Wilson Disease Diagnosed in Infancy: An Appraisal of Available Experience to Generate Discussion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21970993" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Zinc monotherapy from time of diagnosis for young pediatric patients with presymptomatic Wilson disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12774027" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A practice guideline on Wilson disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6842492" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Bioavailability and pharmacokinetics of D-penicillamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17063115" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Diagnosis and management of Wilson's disease: results of a single center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26071888" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Early neurological worsening in patients with Wilson's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16709660" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37116715" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Neurological worsening in Wilson disease - clinical classification and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16864010" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Penicillamine and nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3132218" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Natural course of penicillamine nephropathy: a long term study of 33 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15604549" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Elastosis perforans serpiginosa associated with pseudo-pseudoxanthoma elasticum during treatment of Wilson's disease with penicillamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10777259" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pencillamine-induced elastosis perforans serpiginosa and cutis laxa in Wilson's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12190204" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Elastosis perforans serpiginosa secondary to D-penicillamine treatment in a Wilson's disease patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19170410" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Bullous pemphigoid induced by penicillamine in a patient with Wilson disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11721763" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Iron accumulation in the liver of male patients with Wilson's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11721763" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Iron accumulation in the liver of male patients with Wilson's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9284083" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Metabolism of administered triethylene tetramine dihydrochloride in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25605552" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Prospective pilot study of a single daily dosage of trientine for the treatment of Wilson disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25605552" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prospective pilot study of a single daily dosage of trientine for the treatment of Wilson disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25605552" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Prospective pilot study of a single daily dosage of trientine for the treatment of Wilson disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36183738" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8757970" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Acquired sideroblastic anaemia induced by a copper-chelating agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8435326" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Acquired sideroblastic anaemia during treatment of Wilson's disease with triethylene tetramine dihydrochloride.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7583074" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Long-term treatment of Wilson's disease with triethylene tetramine dihydrochloride (trientine).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11479773" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Ultrastructural identification of iron and copper accumulation in the liver of a male patient with Wilson disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10022625" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Zinc therapy increases duodenal concentrations of metallothionein and iron in Wilson's disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6614680" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Oral zinc therapy for Wilson's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2478589" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Hepatocellular copper toxicity and its attenuation by zinc.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3885271" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Absorption, transport, and hepatic metabolism of copper and zinc: special reference to metallothionein and ceruloplasmin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31388634" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Zinc Maintenance Therapy for Wilson Disease: A Comparison Between Zinc Acetate and Alternative Zinc Preparations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7826266" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Zinc-induced deterioration in Wilson's disease aborted by treatment with penicillamine, dimercaprol, and a novel zero copper diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8280286" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Fatal deterioration of Wilson's disease after institution of oral zinc therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37672695" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Current and Emerging Issues in Wilson's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37672695" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Current and Emerging Issues in Wilson's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20535024" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A clinical assessment of Wilson disease in patients with concurrent liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14713890" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11602847" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Orthotopic liver transplantation for Wilson's disease: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31901209" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Outcomes of Liver Transplant for Adults With Wilson's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20946468" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Liver transplantation for children with Wilson disease: comparison of outcomes between children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24211743" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Long term results of liver transplantation for Wilson's disease: experience in France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32398357" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Liver transplantation as a rescue therapy for severe neurologic forms of Wilson disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32398360" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Liver transplant for neurologic Wilson disease: Hope or fallacy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16123950" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Liver transplantation for Wilson's disease: The burden of neurological and psychiatric disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10714666" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Effect of liver transplantation on neurological manifestations in Wilson disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8198464" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12633149" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16606763" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16606763" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32804913" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Fulminant Wilson Disease in Children: Recovery After Plasma Exchange Without Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12423451" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Review article: the molecular adsorbents recirculating system (MARS) in liver failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24458219" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Effect of molecular adsorbents recirculating system treatment in children with acute liver failure caused by Wilson disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17285615" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Therapeutic plasmapheresis as a bridge to liver transplantation in fulminant Wilson disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18299897" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Single pass albumin dialysis (SPAD) in fulminant Wilsonian liver failure: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32643122" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Late-onset acute liver failure due to Wilson's disease managed by plasmapheresis and hemodiafiltration successfully serving as a bridge for deceased donor liver transplantation: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28859232" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Pregnancy in Wilson's disease: Management and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15216551" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Infant with severe penicillamine embryopathy born to a woman with Wilson disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19014823" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Hypothyroidism and dyshormonogenesis induced by D-penicillamine in children with Wilson's disease and healthy infants born to a mother with Wilson's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10655259" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Treatment of Wilson's disease with zinc. XVII: treatment during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10655282" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Wilson's disease and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18180385" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : ATP7B expression in human breast epithelial cells is mediated by lactational hormones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11241029" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Treatment of Wilson's disease with zinc XVI: treatment during the pediatric years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20967755" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Re-evaluation of the diagnostic criteria for Wilson disease in children with mild liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15448420" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Serum transaminases in children with Wilson's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17904160" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Dominant psychiatric manifestations in Wilson's disease: a diagnostic and therapeutic challenge!</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28433097" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Cognitive and psychiatric symptoms in Wilson disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26575449" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The spectrum of psychiatric symptoms in Wilson's disease: treatment and prognostic considerations.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
